News

MEMO THERAPEUTICS INCREASES SERIES C FINANCING TO CHF 45 MILLION

Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised...

read more

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced a comprehensive, peer-reviewed publication of preclinical data supporting MP0533’s proposed unique mechanism of action (MoA)...

read more

SanaGen, InSphero and Sanquin Awarded with Eurostars Grant for a Breakthrough Gene Therapy, Poised to Become First “Cure” for Severe Alpha-1 anti-Trypsin (AAT) Deficiency (AATD)

Zürich, April 22, 2024 In a notable collaboration that underscores the power of innovation in drug discovery, SanaGen and InSphero, alongside the renowned Sanquin research institute, have been awarded a 1.3 million euro grant for the ambitious project NOCAAVAAT. The NOCAAVAAT project, which aims to develop a breakthrough gene therapy for severe Alpha-1 anti-Trypsin (AAT)...

read more